Intellia Therapeutics Hits New 1-Year Low Time to Sell?

NTLA Stock  USD 8.28  0.99  13.58%   
About 60% of all Intellia Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that some traders are interested. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
Intellia Therapeutics, Inc. shares reached a new 52-week low on Friday . The company traded as low as 13.95 and last traded at 13.97, with a volume of 3666342 shares trading hands. The stock had previously closed at 15.12. Wall Street Analyst Weigh In A number of research analysts recently

Read at thelincolnianonline.com
news
  

Intellia Therapeutics Current Investor Sentiment

Comfort Level 60

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Intellia Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Intellia Therapeutics.

Intellia Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Intellia Therapeutics Historical Investor Sentiment

Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.

Intellia Therapeutics Fundamental Analysis

We analyze Intellia Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Intellia Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Intellia Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intellia Therapeutics stock to make a market-neutral strategy. Peer analysis of Intellia Therapeutics could also be used in its relative valuation, which is a method of valuing Intellia Therapeutics by comparing valuation metrics with similar companies.

Peers

Intellia Therapeutics Related Equities

DNAGinkgo Bioworks   14.73   
0%
100.0%
PRMEPrime Medicine,   6.77   
0%
45.0%
SANASana Biotechnology   6.47   
0%
43.0%
BEAMBeam Therapeutics   6.28   
0%
42.0%
VERVVerve Therapeutics   6.16   
0%
41.0%
CRSPCrispr Therapeutics   5.52   
0%
37.0%
EDITEditas Medicine   4.51   
0%
30.0%
CRBUCaribou Biosciences   3.95   
0%
26.0%
FATEFate Therapeutics   3.00   
0%
20.0%
VRTXVertex Pharmaceuticals   1.20   
8.0%
0%

Complementary Tools for Intellia Stock analysis

When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities